Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the transaction, the chief technology officer now owns 96,790 shares of the company’s stock, valued at $698,823.80. This trade represents a 12.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total value of $92,987.52.

Candel Therapeutics Stock Performance

CADL stock opened at $6.66 on Friday. The company has a market capitalization of $216.32 million, a P/E ratio of -3.85 and a beta of -1.20. Candel Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $14.60. The business has a 50-day simple moving average of $6.61 and a two-hundred day simple moving average of $6.28.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds have recently modified their holdings of CADL. Bank of New York Mellon Corp bought a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $338,000. Rhumbline Advisers bought a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $143,000. Point72 DIFC Ltd bought a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $31,000. Cubist Systematic Strategies LLC bought a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $162,000. Finally, FMR LLC bought a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $46,000. Institutional investors own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $19.00 price target (up previously from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.